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Abstract 
 
Chronic inflammation in response to lipoprotein accumulation in the arterial wall is central in 
the development of atherosclerosis. Both innate and adaptive immunity are involved in this 
process. Adaptive immune responses develop against an array of potential antigens presented 
to effector T lymphocytes by antigen-presenting cells, especially dendritic cells. Functional 
analysis of the role of different T cell subsets identified the Th1 responses as proatherogenic, 
whereas regulatory T cell responses exert antiatherogenic activities. The impact of Th2 and 
Th17 responses is still debated. Atherosclerosis is also associated with B-cell activation. 
Recent evidence established that conventional B-2 cells promote atherosclerosis. In contrast, 
innate B-1 B cells offer protection through secretion of natural IgM antibodies. This review 
discusses the recent development in our understanding of the role of T- and B-cell subsets in 
atherosclerosis, and addresses the role of dendritic cell subpopulations in the control of 
adaptive immunity. 
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Abbreviation List 
APC: antigen presenting cell 
BATF3: Basic leucine zipper transcription factor ATF-like 3 
BST-2: bone marrow stromal cell antigen-2 
cDC: classical dendritic cell 
CTLA-4: Cytotoxic T-Lymphocyte Antigen 4 
CVD : cardiovascular disease 
DAMP: damage-associated molecular pattern 
DC-SIGN: Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin 
DC: dendritic cell  
FcγR: Fc gamma receptors 
Flt3: Fms-like tyrosine kinase 3 
FoxP3: Forkhead/winged helix transcription factor 
GATA:  
GM-CSF: granulocyte-macrophage colony-stimulating factor 
Hsp: Heat shock ptptein 
ICOS: Inducible T-cell COStimulator 
Id3: Inhibitor of DNA binding 3 
IDO: indoleamine 2,3-dioxygenase 
IFN-γ: Interferon- γ  
IL-17R: IL-17 receptor 
IL: Interleukin 
ILC: innate lymphoid cell  
IRA B cell: innate response activator B cell 
LPS: lipopolysaccharide 
LTlymphotoxin  
MDA-LDL: malondialdehyde-LDL 
MHC: major histocompatibility complex 
MIF :migration inhibitory factor 
MZ: Marginal Zone 
NH: Natural helper 
NK natural killer  
NLR: NOD-like receptor 
oxLDL: oxidized LDL 
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PAMP: pathogen-associated molecular pattern 
PD-1: Programmed cell death 1 
pDC: plasmacytoid DC 
RAG: recombination-activating protein 
RLR: RIG-I-like receptor 
ROR: Retinoic-acid-receptor-related orphan receptor 
RUNX1: Runt-related transcription factor 1 
SCID: severe combined immunodeficiency 
SOCS/ Suppressor of Cytokine Signaling 
STAT: signal transducer and activator of transcription 
T-bet: T-box expressed in T cell 
TBX: T-box transcription factor 
Tcf4 : Transcription factor 4 
TCR: T cell receptor 
TGF-β: Transforming growth factor- β 
TLO: tertiary lymphoid organ 
TLR: Toll-like receptor 
TNF-α: Tumor necrosis factor- α 
Treg cell: regulatory T cell 
VH: heavy chain V 
Zbtb46: Zinc Finger And BTB Domain Containing 46 
α-Galcer: α-galactosylceramide  
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I. Introduction 
In his article celebrating the 100th anniversary of the discovery in 1913 of the key role of 
cholesterol in the pathogenesis of atherosclerosis by Nikolai N. Anitschkow, Daniel Steinberg 
reminds us that the young Russian experimental pathologist from Saint Petersburg had already 
anticipated that inflammation might play a role in lesion development 1. If, nowadays, there is 
no doubt that cholesterol is the initiating factor that causes the response to injury leading to 
atherosclerosis, it is also now well-established and accepted that the complex molecular and 
cellular mechanisms that underlie the development and progression of atherosclerotic lesions 
following sub-endothelial lipoprotein accumulation have all the features of those responsible 
for chronic inflammatory diseases.  
Inflammation is an integral part of both innate and adaptive immunity. It consists of a complex 
series of interactions between soluble mediators and cellular effectors that occur in response 
to pathogens or tissue injury, as is the case in atherosclerosis. The innate immune response 
is comprised of a range of soluble factors, including complement proteins, and several cellular 
effectors, including granulocytes, mast cells, macrophages, dendritic cells (DCs), natural killer 
(NK) cells, innate lymphoid cells (ILC) and B-1 cells (Figure 1). Innate immunity is genetically 
fixed and relies on a defined set of receptors, including germline-encoded Toll-like receptors 
(TLRs), NOD-like receptors (NLRs), RIG-I-like receptor (RLRs), C-type lectin and scavenger 
receptors that recognize pathogen-associated molecular patterns (PAMPs) or damage-
associated molecular patterns (DAMPs), the latter being involved in atherogenesis. A number 
of excellent reviews have recently been published on the role of innate immunity in 
atherosclerosis 2-4. In contrast, adaptive immunity is antigen-specific, and relies on a large pool 
of T (CD4+ and CD8+) and B cells expressing antigen receptors whose repertoire is created 
by the somatic recombination of different germline-encoded gene segments. These receptors 
are specific for either microbial derived proteins or processed peptides that are presented in 
association with either class I or class II major histocompatibility complex (MHC). NKT cells 
and γδ T cells are cytotoxic T lymphocytes that function at the intersection of innate and 
adaptive immunity and can recognize lipid and other molecular antigens as well as proteins 
(Figure 1). Several reviews have recently addressed the role of adaptive immunity in 
atherosclerosis 2, 5-8. In this review we will discuss the evidence supporting a role of the different 
components of the adaptive immune system and its control by DCs in atherosclerosis in light 
of the available data from human and animal model studies. 
 
 
II. Role of T cells in atherosclerosis 
II.1. Experimental evidence 
The first evidence that pointed to a role of adaptive immunity in atherosclerosis was the 
widespread expression of the MHC class II, HLA-DR, in human atherosclerotic plaques 9, and 
the presence of a large number of CD3+ T cells in atherosclerotic plaques in humans 10 as well 
as in mice 11, 12. The majority of T cells in mouse and human atherosclerotic plaques are CD4+ 
T-helper cells expressing the αβ T-cell antigen receptor (TCR). CD8+ T cells are also present 
in human atherosclerotic plaques 13, but sparse in mouse lesions 12. T lymphocytes are among 
the earliest cells to be recruited in the atherosclerotic plaque 14. Altogether these early 
observations on the presence of T cells in human and mouse atherosclerotic plaques remained 
associative, and did not show causation. 
Subsequent studies using animal models of atherosclerosis, especially Apoe-/- or Ldlr-/- mice, 
in which human-like atherosclerotic lesions develop spontaneously or in response to high fat 
diet, provided more direct evidence for the participation of adaptive immunity in atherogenesis. 
Apoe-/- or Ldlr-/- mice crossed with immunodeficient mice that lack the V(D)J recombination-
activating protein 1 RAG1 (Rag1-/-) or 2 (Rag2-/-), or have a severe combined 
immunodeficiency (SCID) mutation (scid/scid mice) show, in general, reduced development of 
atherosclerotic lesions when fed a chow diet (reviewed in 5).  These immunodeficient mice that 
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lack both T and conventional B cells are not particularly informative on the role of specific T 
and B cell subpopulations that can be either pro- or anti-atherogenic (see below). One study 
found no difference between immune-competent and –deficient mice fed a high fat diet 15.  
The specific role of T cells was substantiated by experiments showing that the transfer of CD4+ 
T cells into scid/scid/Apoe-/- mice fully reversed the atheroprotection provided by T/B deficiency 
16. However, when the effect of CD4+ T cells was evaluated in CD4-deficient Apoe-/- mice, 
contrasting results were reported. Female CD4-/-Apoe-/- mice exhibited markedly larger lesions 
in the descending thoracic aorta, but no effect was observed in the aortic root, as compared 
with wild type Apoe-/- mice 17. Intriguingly, in a subsequent study using the same CD4/Apoe 
double knockout mice, atherosclerosis in the aortic sinus was reduced, but the authors made 
no mention of the effect of CD4+ T cell deficiency on atherosclerosis in the aorta 18. Of note, 
in both studies, the CD8+ cell population and the titers of anti MDA-oxidized LDL (oxLDL) IgM 
antibodies were increased. CD8+T cells were recently shown to promote the development of 
vulnerable atherosclerotic plaques 19, whereas natural anti-oxLDL IgM autoantibodies are 
atheroprotective (reviewed in 20; see below). 
The specific recognition of peptide antigens presented by MHC molecules triggers TCR 
signaling, but co-stimulatory and co-inhibitory receptors on T cells direct T cell function and 
determine T cell fate. These co-signaling molecules are members of the immunoglobulin 
superfamily, including B7(CD80/86), CD28, PD-1 and CTLA-4, and the tumor necrosis factor 
receptor superfamily, including CD40, CD27, OX40, and CD137. Experiments aimed at 
investigating the role of co-signaling molecules provided further evidence for a role of T cells 
in atherogenesis (reviewed in 21, 22, see below IV.2). For example, blockade of the OX40-
OX40L interaction by anti-OX40L antibody treatment in Ldlr-/- 23 or Apoe-/- mice 24 reduced 
atherosclerosis. Yet, blockade of T cell activation was accompanied by an enhanced B-1 cell 
activity and increased atheroprotective anti-oxLDL natural IgM antibodies. This was also the 
case in Ldlr-/- mice deficient in CD74, a membrane chaperone that regulates antigen 
presentation and T-cell activation by associating with MHC class II molecules, but also serves 
as cell surface receptor for macrophage migration inhibitory factor (MIF) 25. The expression of 
several co-signaling molecules is not exclusively confined to adaptive immune cells and thus 
global knockout models can also impact both innate immune and vascular cell activation. For 
instance, CD40 is widely expressed on non-hematopoietic cells, including endothelial cells, 
fibroblasts, and epithelial cells 26 as well as on platelets, and CD137 is expressed by 
endothelial and smooth muscle cells 27.  
The specificity of the T-cell response in atherosclerosis is a complex issue. The inflammatory 
process that prevails in the plaque might promote the recruitment of heterogeneous polyclonal 
T cells. However, analysis of T cells derived from Apoe-/- mice showed a highly restricted 
TCR-repertoire pointing to a specific antigen-driven process 28, and TCR deficiency in 
Apoe-/- mice has been shown to be atheroprotective 17. T cells isolated and cloned from human 
plaques respond to oxLDL in a MHC class II (HLA-DR)-restricted manner 29, making oxLDL 
the principal candidate antigen in atherosclerosis. In support of this, the transfer of T cells 
sensitized to oxLDL into scid/scid/Apoe-/- mice accelerated atherosclerotic lesion development 
16. T-cells isolated from human early atherosclerotic lesions (iliac arteries) or late lesions 
(common carotid) also react to Heat shock protein (Hsp)60 and recognize Hsp60-derived 
peptides 30. However, transfer of effector T-cells recognizing antigens not specific to 
atherosclerosis can also be proatherogenic: CD4+ T cells from systemic lupus erythematous 
(SLE)-susceptible mice transferred into Ldlr-/- mice increased atherosclerosis 31. SLE 
autoantigens are most often those of nuclear origin, thus supporting a potential role for 
nucleus-derived autoantigens in atherosclerosis as well as SLE. Also, patients with 
autoimmune disorders, such as rheumatoid arthritis 32, SLE 33 or psoriasis 34, have an 
increased risk of cardiovascular disease (CVD). This co-morbidity cannot be accounted for by 
traditional cardiovascular risk factors, and further supports evidence that atherosclerosis 
shares similar disease mechanisms with these autoimmune disorders, including dysregulation 
of the adaptive immune system.   
Altogether, it is clear that the adaptive immunity is activated and participates in atherosclerosis, 
but some points are often neglected. Modulation of T, B and DC numbers has complex effects 
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on lipoprotein metabolism, which might directly influence atherosclerosis. Total plasma 
cholesterol levels were significantly lower in Rag2-/- Apoe-/- mice 35, as compared with 
immunocompetent mice. Similarly, LDL cholesterol levels were slightly lower in CD74-/- Ldlr-/- 
mice that are deficient in T cells 25. As a result, part of the atheroprotection offered by T cell 
depletion or deactivation of the immune system might be elicited by a reduction in cholesterol 
levels. The lipoprotein and plasma lipid differences in immunodeficient mice are likely due to 
the reduced inflammatory status of these mice and altered spectrum of pro-inflammatory 
cytokines, which affect lipoprotein metabolism and/or catabolism 36. Also, the roles played by 
the adaptive immunity are site-specific and time-dependent in animal models, which likely also 
holds true for humans. No differences in lesions were observed in the brachiocephalic artery 
whereas in the aortic sinus of immune-deficient mice the lesions were smaller as compared 
with immunocompetent Apoe-/- mice 35. Moreover, T cells seem to play a rather minor role in 
advanced lesion growth in mice: atherosclerosis in the aortic sinus was reduced in immune-
deficient Apoe-/- mice fed a chow diet but not in those fed a Western diet 15, 37, and early lesions 
(8 weeks) were smaller in Rag1-deficient Ldlr-/- mice but late lesions (16 weeks) did not show 
any significant difference 38. Although understanding plaque growth is critical to better 
understanding disease etiology, causes of plaque stability and rupture are a more immediate 
target clinically. This is much harder to model in animals, although several protocols exist 39, 
but evidence in human atherosclerosis suggest an important association of infiltrated T cells 
with unstable plaques. Unstable plaques are associated with immune-inflammatory features 
including increased levels of T cells 40 and DCs 41. 
 
II. 2. T cell subsets 
Upon engagement of their TCR with the antigen-MHC complex displayed on the surface of an 
antigen presenting cell (APC), naïve CD4+ T lymphocytes differentiate into various effector or 
regulatory subsets, depending on the specific micro environment of co-signaling and cytokines 
(Figure 2). These cells elicit distinct functions and display specific profiles of cytokine 
production. 
 
Th1 cells  
For a long time, it was believed that naïve CD4+ T cells polarize towards either Th1 or Th2 
lymphocytes according to mutually exclusive differentiation programs. Th1 commitment is 
mainly triggered by IFN-γ and IL-12. Terminally differentiated Th1 cells are characterized by 
the expression of the transcription factor T-box transcription factor (TBX)-21 (also referred to 
as T-bet) and the production of IFN-γ. IL-12 triggers the two key lineage defining transcription 
factors: signal transducer and activator of transcription (STAT-4) and T-bet. In turn, T-bet 
induces the production of IFN-γ and the expression of the high affinity IL-12 receptor, while 
down regulating the expression of IL-4 and IL-5, characteristic of type 2-dominated responses. 
Th1 cells are generally involved in immunity against intracellular pathogens, but have also 
been implicated in several autoimmune and inflammatory diseases including atherosclerosis.  
Th1 are the most abundant T-cell subtype in human atherosclerotic plaques 42. They exhibit 
signs of activation; they secrete cytokines such as IFN-γ, TNF-α and IL-2, and may proliferate 
in situ 43. The hallmark cytokine produced by Th1 cells, IFN-γ, can exert diverse pro-
atherogenic actions (reviewed in 43, 44). IFN-γ activates macrophages and DCs, which improves 
the efficiency of antigen presentation and promotes further Th1 polarization. Genetic deficiency 
in IFN-γ or its receptor in Apoe-/- mice reduced lesion formation and enhanced plaque stability 
via increased collagen content 45, whereas exogenously administered IFN-γ accelerated 
atherosclerosis 46. Intriguingly, it seems that the protective effect of IFN-γ deficiency is 
restricted to male mice 47. Pro-inflammatory effects of IFN-γ are mainly mediated through 
activation of the transcription factor STAT-1. Consistently, chimeric mice generated by bone 
marrow transplantation from STAT-1-deficient Apoe-/- mice into Apoe-/- mice displayed reduced 
lesion formation 48, 49. These animal studies have been widely used to demonstrate that 
atherosclerosis is a Th1-driven inflammatory disease. However, although IFN-γ expression is 
restricted to lymphoid cells in mice, it is not only produced by Th1 cells, but also by NKT and 
NK cells as part of the innate immune response. NKT cells have been shown to be 
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proatherogenic (see below). The role of NK cells remains relatively unexplored and 
controversial 50, 51. 
IL-12 produced by DCs is essential for Th1 differentiation and induction of T-bet. Interestingly, 
exogenous administration of IL-12 augmented IFN-γ levels in the aorta and accelerated 
atherosclerosis 52. However, Apoe-/- mice deficient in IL-12 showed a marked reduction in 
atherosclerosis, which was only evident in early stages but not in more advanced lesions 53, 
reminiscent of what is observed in immunodeficient mice. Yet, because these mice were 
deficient in IL12p40, the common subunit of IL-12 and IL-23, a role for IL-23 cannot be ruled 
out. 
In addition to IL-12, IL-18 also promotes T-bet expression and subsequent Th1 cell 
development. Injection of IL-18 accelerated atherosclerosis 54, while treatment of Apoe-/- mice 
with a plasmid encoding an endogenous IL-18 inhibitor significantly reduced atherosclerosis 
55.  Furthermore, IL-18 deficient Apoe-/- mice showed a marked reduction of atherosclerotic 
lesions and diminished Th1 cell activity, as illustrated by a switch from Th1 related antibody 
isotypes IgG2a to Th2 related antibody isotypes IgG1 56. 
The Th1/Th2 switch has been widely used to ascertain the proatherogenic effect of Th1 and 
the anti-atherogenicity of Th2. Indeed, deficiency of T-bet in Ldlr-/- mice, which causes a switch 
to Th2 and a change in antibody responses, reduced lesion development 57. Also Apoe-/- mice 
on a BALB/c background, which display predominant Th2 responses, showed reduced 
atherosclerotic lesions at all time points studied 58. Other genetic manipulations were used to 
investigate the effect of Th1/Th2 switch on atherosclerosis. Transgenic C57BL/6 mice with 
changes in MHC class II antigens to decrease Th1 and increase Th2 expression under high 
fat diet containing cholate displayed smaller atherosclerotic lesions than wild type mice 59. 
Moreover, BALB/c mice deficient in STAT-6, which mount dominant Th1-cell responses 
developed atherosclerotic lesions comparable to C57BL/6J mice on the same diet 59, 60. All 
these findings were often interpreted as evidence for an antiatherogenic effect of Th2 
responses, when in fact they demonstrate that a Th1/Th2 switch alleviates the proatherogenic 
effects of Th1. In the case of T-bet deficiency studies, a note of caution is that T-bet is also 
expressed by type 1 innate lymphoid cells (ILC1), including NK cells 61. 
 
Th2 cells 
Th2 differentiation is induced by DCs through IL-6 and IL-13 secretion and OX40-OX40L 
interaction 62. Th2 cells play an essential role in B cell-mediated humoral responses, especially 
against extracellular pathogens. They secrete IL-4, IL-5, and IL-13, and can also produce IL-
10. Yet, IL-10 is mostly produced by macrophages, and regulatory T and B cells. IL-5 and IL-
13 are also not exclusive to adaptive T cells and can be abundantly secreted by ILC2 61. STAT-
6 activation by IL-4 induces expression of the master Th2 differentiation transcription factor 
GATA-3 63, which upregulates IL-4 and IL-5, and inhibits the production of IFN-γ. 
Consequently, Th2 cells might counteract the pro-atherogenic Th1 effects. Yet, GATA-3 is also 
important in ILC2 64 and ILC3 65 differentiation. 
Recent data have shown that IL-9 is produced by a newly defined T cell subpopulation, Th9 
cells that are reprogrammed from Th2 by TGF-β 66. Patients with acute myocardial infarction 
have increased IL-9 plasma levels, and carotid atherosclerotic plaques display increased 
mRNA levels of IL-9 and IL-9 receptor as compared with normal vessels 67. Further studies are 
required to elucidate the role of IL-9 and Th9 in atherosclerosis. 
As seen above, the role of Th2 in atherosclerosis is rather difficult to establish in a 
straightforward manner. In particular, if Th2 cells were anti-atherogenic, deficiency in IL-4, the 
prototypical Th2 cytokine, should result in accelerated atherosclerosis. In contrast, Ldlr-/- 
transplanted with bone marrow from IL-4 deficient mice showed reduced atherosclerosis in a 
site-specific manner, compared to mice transplanted with IL-4 competent bone marrow 68. 
Similar results were documented in Apoe-/- mice lacking IL-4, suggesting a pro-atherogenic 
role of Th2 53. However, in a second study the exogenous administration or genetic deficiency 
of IL-4 had no effect on lesion development in both hypercholesterolemic and angiotensin II 
induced atherosclerosis 69. Overall, these studies that evaluated the effect of IL-4 deficiency 
on atherosclerosis suggest that the lack of Th2 responses does not promote atherosclerosis, 
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and may even be protective. Yet, a not of caution should be sounded here, since IL-4 is also 
made by mast cells, and mast cells contribute to atherosclerosis 70. 
Another prototypical Th2 cytokine is IL-13, which is also produced by other cell types, including 
NK cells, eosinophils, basophils, mast cells, macrophages 71 and ILC2 61. Its effect on 
atherosclerosis has been recently investigated. Chimeric Ldlr-/- mice transplanted with bone 
marrow from IL-13-/- mice developed larger atherosclerotic lesions than Ldlr-/- mice 
reconstituted with wild type bone marrow, which was associated with a selective decrease in 
IL-4 and IL-10, no change in IL-5 and IFN-γ production and a significant increase in Th1-
dependent IgG2c antibodies in serum 72. Moreover, IL-13 administered to Ldlr-/- mice for a short 
period of time at a dose that did not modify the Th1/Th2 balance had no effect on plaque size, 
but lesions were more stable and less inflammatory, which highlights the pro-fibrotic and anti-
inflammatory properties of IL-13, independently of its effect on the adaptive immune system.  
IL-19, a member of the IL-10 family of cytokines, produced by monocytes and other non-
immune tissue cells under inflammatory conditions, has been shown to polarize the T cell 
response towards Th2 73. IL-19 decreased atherosclerosis in Ldlr-/- or Apoe-/- mice, and the 
expression of the Th1 markers T-bet and IFN-γ was reduced in splenocytes from mice injected 
with IL-19 74. 
Several studies support a protective role of IL-5 producing Th2 cells in atherosclerosis. MDA-
modified LDL vaccination of Apoe-/- mice reduced atherosclerosis via secretion of IL-5 and 
increased production of anti-oxLDL IgM antibodies, while IL-5 deficiency inhibited the 
protective effect of vaccination by blocking the production of anti-oxLDL antibodies 75. 
Moreover, blockade of IL-5 by neutralizing anti-IL-5 antibodies abolished the atheroprotective 
effect of IL-33 administration in Apoe-/- mice, which was associated with increased production 
of Th2 cytokines and anti-oxLDL IgM antibodies 76. Even though these studies highlighted the 
anti-atherogenic properties of IL-5, they did not clearly identify the source of IL-5 as Th2 cells. 
Interestingly, the natural immunity associated with the production of atheroprotective anti-
oxLDL IgM was impaired in Apoe-/- mice deficient in Id3 due to reduced IL-5, resulting in 
increased atherosclerosis 77. However, IL-5 was not generated from Th2 or mast cells, but from 
natural helper (NH) cells, a subset of ILC2 77, 78. ILC2 include NH cells, multi-potent progenitor 
type 2 cells, nuocytes or innate type 2 helper cells 61 They are RORγ-independent, and require 
Id2, IL-7, RORα, and the common cytokine receptor γ-chain for their development. They 
produce Th2 cytokines, most notably IL-5 and IL-13, but not IL-4, in response to IL-25 and IL-
33. The role of ILCs in atherosclerosis needs to be explored. 
In conclusion, most of the studies that highlighted the anti-atherogenic effect of Th2 cells were 
biased by the concomitant decrease in Th1 responses or did not definitely identify the source 
of type 2 cytokines as Th2 cells and not ILC2. 
 
Th17 cells 
In recent years, Th17 cells have emerged as a new CD4+ T cell subset, leading to a revision 
of the Th1/Th2 paradigm. Differentiation of naïve T cells into Th17 requires the nuclear receptor 
ROR-γt and depends on other transcription factors, including ROR-α, STAT-3, Aryl 
hydrocarbon receptor, and runt-related transcription factor 1 (RUNX1) 79. Th17 cells produce 
large quantities of IL-17A and exhibit effector functions distinct from Th1 and Th2 lymphocytes. 
In addition to the signature cytokine IL-17A, Th17 cells produce IL-17F, IL-22 and IL-23. TGF-
β and IL-6 are necessary for Th17 differentiation, while IL1-β is instrumental for human Th17 
development. IL-21 and IL-23 are required for Th17 proliferation and maintenance, 
respectively. IL-23 stabilizes the inflammatory phenotype of Th17 cells 80. IL-6 activates STAT-
3, which is required for ROR-γt expression and function. IL-6 drives the effect of TGF- toward 
the development of Th17 cells instead of promoting that of Treg cells 81. The Th1 transcription 
factor T-bet might repress Th17 development by blocking the transcription of ROR-γt 82. 
Furthermore, Th1 and Th2 cytokines, IFN-γ and IL-4 may directly suppress Th17 
differentiation, while IL-17 inhibits Th1 polarization, IFN-γ production and T-bet expression 83. 
Recently, a new role for platelet-derived PF4 in blocking Th17 differentiation has been revealed 
84. 
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Th17 cells are important to clear extracellular bacteria and fungi by activating neutrophils 
through the production of IL-17A and IL-17F. They are also involved in the development of 
inflammatory bowel diseases, autoimmune diseases such as rheumatoid arthritis and 
experimental autoimmune encephalomyelitis 85, whereas cytokines secreted by Th17 cells, 
including IL-22 and IL-23 may restrain inflammatory responses during microbial infection and 
allergy 86, 87. Accumulation of Th17 cells and IL-17 has been observed in murine 88-90 and 
human 88, 91-93 atherosclerotic lesions. The expression of IL-17 in human carotid lesions was 
associated with a stable plaque phenotype 88, 93, but another study showed a positive 
correlation of IL-17A expression and plaque instability 92. 
The role of IL-17 has been investigated in several mouse models of atherosclerosis, but results 
are conflicting with pro- and anti-atherogenic effects attributed to Th17 (reviewed in 94). A pro-
atherogenic role of Th17 was suggested in Apoe-/- mice deficient in Fcγ chain, which developed 
less atherosclerosis, associated with less Th17 cells and reduced IL-17 secretion by activated 
CD4+ T-cells 95. The protective effect was accompanied by increased Treg cells that produced 
more TGF-β and IL-10 95.  
Neutralizing experiments with anti-IL-17 antibodies or genetic deficiency of IL-17A in mouse 
models provided more direct evidence for a role of Th17 in atherosclerosis. Blocking IL-17 with 
polyclonal anti-IL-17 neutralizing antibodies raised in rats or goats resulted in significant 
reduction, whereas rIL-17 treatment augmented atherosclerosis in Apoe-/- mice 96, 97. It is 
noteworthy that blocking IL-17A in these studies did not alter the signaling pathway, which 
might be accounted for by the use of polyclonal non-murine antibodies. On the contrary, 
blockade of IL-17A with mouse monoclonal anti-IL-17A antibodies that abolished IL-17A 
signaling did not affect atherosclerosis in Ldlr-/- mice that have low levels of IL-17 88, 98, whereas 
treatment with rat anti-IL-17A did not abolish IL-17A signaling but reduced atherosclerosis 98. 
In Ldlr-/- mice with SOCS3 deletion in T-cells, which specifically promotes T cell polarization 
toward Th17, IL-17 production was increased and atherosclerosis markedly reduced 88. 
Interestingly, in these mice anti-IL-17A treatment with a mouse monoclonal antibody not only 
blocked the beneficial effect of Th17 polarization but accelerated atherosclerosis beyond that 
in wild type Ldlr-/- mice 88. In agreement with this finding, IL-17A was found to induce a stable 
plaque phenotype in Ldlr-/- mice transplanted with bone marrow from mice with a T cell-specific 
deletion of Smad7, a potent inhibitor of TGF-β signaling 93. These mice displayed a Th17 
profile, as indicated by the detection of RORγt and increased IL-17A expression in draining 
lymph nodes 93. 
Treatment with adenovirus encoding IL-17 receptor A (IL-17RA) reduced atherosclerosis in 
Apoe-/- mice 89. However, no direct evidence for a sustained blockade of IL 17 signaling was 
reported in this study. Also, Ldlr-/- mice transplanted with bone marrow from mice deficient in 
IL-17R showed smaller atherosclerotic lesions, associated with decreased mast cells, and 
reduced IL-6 and increased IL-10 levels 99. Yet, interpretation of this finding should be done 
with care, because IL-17R-/- mice have been shown to produce more IL-17A due to the 
disruption of negative feedback inhibition 100, which means that the anti-atherosclerotic effect 
of myeloid IL-17R deficiency might be due to increased IL-17A levels, acting on non-
hematopoietic cells.  
Genetic deficiency in IL-17A in Apoe-/- mice also provided conflicting results that are difficult to 
explain. Usui et al. observed reduced atherosclerosis in IL17A deficient Apoe-/- mice fed a no 
cholate/high-fat diet for 12 weeks 101 whereas Danzaki et al. reported exaggerated 
atherosclerosis in IL17A Apoe-double knockout mice fed similar diet for 8 or 16 weeks, which 
was associated with increased IFN-γ and decreased IL-5 production by splenic CD4+ T-cells 
102; Madhur et al. found no effect in IL17A deficient Apoe-/- mice fed cholate containing high fat 
diet for 12 weeks 103. 
One possible explanation for the contradictory findings reported so far in the literature is that 
IL-17A is produced not only by T-cells but also by innate T cells and vascular cells, and not 
only immune cells are targets of IL-17. Therefore, studies with global deficiency in IL-17, 
treatment with neutralizing anti-IL-17 antibodies or administration of recombinant IL-17 do not 
allow conclusions on the specific role of Th17 in atherosclerosis.  Nevertheless, it seems that 
in Th1-driven autoimmune diseases, such as atherosclerosis or T-cell induced enterocolitis 83, 
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IL-17 produced by Th17 cells have beneficial effects by inhibiting Th1 cell activation after 
binding to IL-17R expressed on Th1 cells and repressing T-bet expression 104. As a result, 
pathogenic Th1-associated molecules, such as IFN-γ and IL-12 receptor β2 subunit, are 
inhibited. In addition, the most recent data indicate that IL-17A promotes collagen synthesis 93, 
105, whereas IFN-γ is known to inhibit it 106, which could account for the plaque-stabilizing effect 
of Th17 cells. 
In humans, low levels of IL-17 in patients with acute coronary syndromes were associated with 
increased risk of death and myocardial infarction 107. Data in mice and humans reveal a critical 
contribution of Th17-associated cytokines, IL-23 and IL-17, in rheumatoid arthritis and 
psoriasis. Anti-IL 17 and anti IL-12/23p40 antibody therapy is currently under evaluation in this 
setting. Given the potentially adverse effects of IL-17 blockade in atherosclerosis, a note of 
caution should be considered when treating patients with inhibitors of the IL-17 pathway. 
 
Treg cells 
Several subsets of CD4+ T cells with immunosuppressive activity have been described. The 
naturally occurring regulatory T (Treg) cells are generated during T cell development in the 
thymus, while induced Treg (iTreg) cells can be generated in the periphery from naïve CD4+ 
T cells. Treg cell generation essentially depends on TGF-β, together with TCR costimulatory 
signals (mainly CTLA-4 on Treg with CD80/86 on APCs), and IL-2. Treg cells express the 
forkhead/winged helix transcription factor (FoxP3) that is required for their development and 
functions. Treg cells are essential in the control of autoimmunity and the maintenance of self-
tolerance. They are capable of suppressing the activation of effector T-cells, by direct 
interaction or through inhibition of APCs, resulting in the regulation of both priming and 
execution of T effector responses. The immune suppressive actions of Treg cells are generally 
transmitted through cellular contact and/or secretion of the anti-inflammatory cytokines IL-10, 
TGF-β, and IL-35.  
Human atherosclerotic lesions contain only limited Treg cell numbers (1–5% of all T-cells) 
compared to other chronically inflamed tissues, where up to 25% of T-cells are 
immunosuppressive T cells 108. Patients with coronary artery disease (CAD) have reduced 
peripheral Treg cell numbers, determined as either CD4+CD25+Foxp3+ 109, CD4+CD25high 110 
or CD4+TGF-β+ Th3 cells 111. Functional properties of Treg cells appear to be compromised in 
CAD. They expressed less Foxp3 and CTLA4 and exhibited less immune suppressive 
capacities in vitro 110. Also, Apoe-/- mice have fewer Treg cells in the spleen and demonstrate 
impaired Treg cell suppressive function, compared to C57BL/6 mice 112. Importantly, while local 
aortic Treg cell levels initially increase, the latter were reduced and the local effector T/Treg 
cell ratio greatly enhanced after 8-week feeding with high fat diet in Apoe-/- mice 113. This effect 
was reversed by switching to a chow diet.  
A large body of evidence now exists showing that Treg cells exert a protective role in 
atherosclerosis. The principal Treg cytokines IL-10 and TGF-β have been shown to induce 
potent anti-atherogenic activities. Genetic inactivation, or blockade of IL-10 or TGF-β with 
neutralizing antibodies, aggravated atherosclerosis in mice, with enhanced vascular 
inflammation and exacerbation of pathogenic Th1 and Th2 responses 114-118. Yet, these earlier 
studies did not provide direct evidence for a role of Treg cells in atherosclerosis, since both 
TGF and IL-10 are mainly produced by macrophages.  Subsequent studies addressed this 
issue. Targeted inactivation of TGF-β signaling specifically in T cells markedly enhanced 
atherosclerosis, suggesting an important role for this cytokine produced by Treg cells in 
atherosclerosis 119, 120. Depletion of Treg cells points to a protective role of these cells in 
atherosclerosis. Significant aggravation of atherosclerosis is observed in mice with reduced 
Treg cell numbers, achieved by deletion of CD80/86, CD28, ICOS or after treatment with 
CD25-neutralizing antibodies 121, 122. Other strategies for Treg cell ablation, including 
antisense-induced Treg cell apoptosis, vaccination of mice against Foxp3 123, or use of mice 
expressing the diphtheria toxin receptor under control of the Treg-specific Foxp3 promoter 124, 
also lead to increased vascular inflammation and atherosclerosis. It is noteworthy that this 
latter study is difficult to interpret because Treg depletion increased atherogenic lipoprotein 
levels. On the contrary, adoptive transfer of CD4+CD25+ Treg cells 121, 125 or IL-10 producing 
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Tr1 cells 126 reduced atherosclerotic lesion development in Apoe-/- mice. Similarly, expansion 
of Treg cells by blocking the chemokine CCL17, whose expression by DCs restrains the 
homeostasis of Treg cells, reduced the progression of atherosclerosis 127. 
Treg cells can directly inhibit the pro-inflammatory phenotype of macrophages resulting in 
reduced foam cell formation and differentiation of macrophages towards an anti-inflammatory 
M2 phenotype 128. They can also directly regulate endothelial cell activation and leukocyte 
recruitment, independent of their suppressive functions on effector T-cells 113.  
Overall, recent studies strongly suggest that the protection by Treg cell-mediated immune 
tolerance is hampered in atherosclerosis, and that immunomodulatory strategies aimed at the 
induction of self-tolerance should be able to limit the development of the disease. Induction of 
peripheral tolerance against selected antigens is currently under evaluation to prevent or treat 
autoimmune, inflammatory, or allergic diseases 129. 
 
Induction of tolerance in atherosclerosis 
Approaches to induce tolerance in the context of atherosclerosis have focused on a few 
selected antigens, mainly oxLDL, ApoB-100 peptides or Heat shock proteins. Injection of 
oxLDL at birth to newborn Apoe-/- mice reduced the immune response to oxLDL and the 
development of atherosclerosis 130. Nasal, oral or subcutaneous administration of small doses 
of mycobacterial Hsp65 in Ldlr-/- mice reduced atherosclerotic lesion development 131, 132. 
Mucosal administration of oxLDL, Hsp60, or ApoB-100 peptides fused to the B subunit of the 
cholera toxin (which served as a carrier protein) also attenuated atherosclerosis 133-136. The 
induction of tolerance in these models was associated with an increase in Treg cells and TGF-β 
production, IL-10 production, or both. 
Based on the observation that long-term subcutaneous infusion of adjuvant-free, low-dose 
influenza HA (107-119) peptide transformed mature effector Th cells into CD25+ Treg cells 137, 
we recently reported that subcutaneous infusion of low doses of ApoB-100-derived peptides 
in Apoe-/- mice for 2 weeks markedly inhibited plaque development and progression 138. The 
treatment was associated with a promotion of antigen-specific Treg cells and a reduction in 
cytokine production by Th1 and Th2 cells. Although no direct evidence that changes in antigen-
specific Treg responses are responsible for disease prevention has yet been provided, these 
studies suggest that novel therapeutic approaches based on the enhancement of the Treg 
population in atherosclerosis might be feasible. 
Other strategies exist to expand Treg numbers. Antibodies directed against the T-cell marker 
CD3 can reconstitute self-tolerance in established autoimmune diseases, such as type 1 
diabetes mellitus 139. Intravenous or oral anti-CD3 therapy reduced atherosclerotic lesion 
development in Ldlr-/- mice 140. This beneficial effect was associated with enhanced TGF-β and 
Foxp3 mRNA expression in lymphoid organs, as well as with an increase in the subset of Treg 
cells that expressed latency-associated peptide 141.  
Treatment with low dose IL-2 promoted Treg recovery and clinical improvement in patients with 
autoimmune vasculitis 142. In Apoe-/- mice, functional delivery of IL-2 to pre-established 
atherosclerotic lesions 143 or IL-2/anti-IL-2 mAb (JES6-1) treatment 144, 145 resulted in plaque 
reduction mediated by Treg expansion. 
On the basis of studies demonstrating that calcitriol, an active form of vitamin D3, can induce 
tolerogenic immune responses, calcitriol has been orally administered to Apoe-/- mice to induce 
Treg and tolerogenic DCs, which was accompanied by slower progression of atherosclerosis 
146.  
The measles virus is known to suppress the immune system through inhibition of dendritic cell 
activation, decreased IL-12 production, and reduced effector-Th-cell proliferation 147. Apoe-/- 
mice treated with nucleoprotein from the measles virus had a marked inhibition of 
atherosclerosis and promotion of a Tr1-cell response 148. Mycobacterium bovis BCG killed by 
extended freeze-drying injected to Apoe-/- or Ldlr-/-mice showed atheroprotective effects 
through IL-10 production and Treg cell expansion 149. 
 
NKT cells 
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NKT cells are a distinct subset of T-cells expressing both natural killer and T-cell markers. 
Unlike T-cells, which recognize peptide antigen presented by MHC molecules, NKT cells 
recognize lipid antigens presented by the hydrophobic MHC-like molecule, CD1d expressed 
on APCs. One of the well-studied and the major subset of NKT cells is type 1, also called 
invariant NKT-cells (iNKT), which are characterized by an invariant TCRα chain (Vα24Jα18) 
paired with one of a small number of TCR chains. iNKT-cells play a major role in bridging the 
innate and adaptive immune responses. They are constantly activated and respond 
immediately upon antigen encounter.  
To elucidate the direct role of NKT cells in atherosclerosis, mouse models of CD1d deficiency 
were used. These mice lack both variant and invariant NKT-cells. NKT cells were also 
selectively activated by using the synthetic glycolipid α-galactosylceramide (α-Galcer). Both 
chronic deficiency (CD1d-/-) and acute activation of NKT cells in Apoe-/- or Ldlr-/- mice confirmed 
their pro-atherogenic effects 150-152. However, this effect was observed only in the early but not 
in the advanced stages of atherosclerosis 151, 153. Adoptive transfer of splenocytes from NKT-
cell enriched Vα14Jα18 TCR transgenic mice in Rag-/-Apoe-/- mice resulted in increased 
atherosclerotic lesions compared to recipients transplanted with NKT cell deficient splenocytes 
154. Jα18-/-Ldlr-/- mice that are depleted in iNKT cells had markedly reduced atherosclerosis and 
IFN-γ expression in lesions 155. Altogether these studies indicate that NKT cells are pro-
atherogenic. However, in one study, activation of NKT cells by α-Galcer (combined i.p. and 
i.v.administration) reduced lesions in a model of collar-induced carotid atherosclerosis in Ldlr-
/- mice, while no effect was found in Apoe-/- mice 156. In this model, α-Galcer administration in 
LDLr-/- mice, but not in apoE-/- mice, increased CD3+IL-10+ cells in spleen and mediastinal 
lymph nodes. No change in CD3+IFN-+ cells and CD3+IL-4+ cells was observed, while in other 
studies in which α-Galcer was proatherogenic, IL-4 and IFN- production increased 150-152, 
which could account for the discrepancy. 
Given the proatherosclerotic role of NKT cells, therapeutic applications involving NKT cell 
depletion might have beneficial effects. 
 
 
III. Role of B cells in atherosclerosis 
III.1. B cell ontogeny 
B cell characterization has been strongly improved during the last two decades with the 
identification of several distinct B cell subsets based on their origin and function. Conventional 
B-2 cells that form the dominant B cell population in adult spleen (>85%) and lymph nodes 
include CD5-CD19+CD23+CD43-IgMlowIgDhigh Follicular (F) B cells and CD5-CD19+CD23-CD43-
IgMhighIgDlow Marginal Zone (MZ) B cells. B-2 cells originate from bone marrow precursors and 
contribute to T-cell dependent humoral and adaptive immune responses. B-2 cell responses 
are highly specific but delayed 157.  
A minor population of B cells, B-1 cells, has been described in different organs, mainly in the 
spleen (5%) and the peritoneal/pleural cavities. The B-1 cell population derives from 
splanchno-pleural area and fetal liver, and differentiates into CD5+CD19+CD23-
CD43+IgMhighIgDlow B-1a and CD5-CD19+CD23-CD43+IgMhighIgDlow B-1b cells in mice 158. 
Unlike B-1b cells, B-1a cells are less efficiently reconstituted from bone marrow progenitors 
and may differ in terms of immunoglobulin structure, VH usage and repertoire selection when 
they originate from B-1 cell-restricted bone marrow precursors 158, 159 , 160. There are several 
substantial differences between B-1 cells and other B cells 157, 159. Briefly, B-1 cells are long-
lived, non-circulating lymphocytes and have reduced antigen diversity and affinity compared 
to B-2 cells. B-1 mediated-immune responses are rapid but poorly specific. B-1a cells secrete 
natural IgM antibodies, which contribute to T-cell independent humoral immune responses. 
The low affinity antibodies produced by B-1a cells are polyreactive and constitute the first line 
of defense against bacterial pathogens, with a major proportion reacting with oxidized lipid 
moieties 4. 
Although earlier studies had already reported immunosuppressive properties of B cells, the 
existence of a specific B cell subpopulation with regulatory properties (Breg) was only recently 
demonstrated 161. At this moment a clear characterization of the Breg population is still lacking 
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since Breg cells share some functional (IL-10 production) and phenotypical (CD19+CD5+) 
characteristics with B-1a cells or MZB cells 161, 162. A new subset of B-1a cells, innate response 
activator (IRA) B cells, has been recently identified 163. B-1a cells migrate from the peritoneal 
cavity to the spleen where they develop into IRA B cells and produce granulocyte-macrophage 
colony-stimulating factor (GM-CSF) 163, 164. 
 
III.2. B cell infiltration in atherosclerotic lesions 
B cells have been identified at different stages in mouse atherosclerotic lesions 165, 166, but only 
in advanced plaques in humans 167, 168. By immunohistochemistry, mature CD22+ or CD20+ B 
cells have been detected in both intima and adventitia of human atherosclerotic plaques. A 
recent report concluded that these B cells are most likely B2-derived plasmablasts, with 
evidence of local affinity maturation occurring in both adventitia and plaque, and the presence 
of a limited number of class-switched clones 169. However, in old Apoe-/- mice, CD19+B cells 
mainly accumulated in the adventitia close to advanced lesions with a nodular organization, 
called tertiary lymphoid organs (TLOs) 167, 170. B cells were the major cells populating aortic 
TLOs, which contrasts with their minor presence (compared to T-cells and macrophages) 
within atherosclerotic plaques. These aortic TLOs develop close to the abdominal aorta and 
could be important for the generation of local humoral responses 171. CCR-6 is required for B 
cell homing to the aorta 165. Aortic TLOs are not present in early lesions in young Apoe-/- mice, 
but develop in old animals 171 with advanced lesions, suggesting a specific role in the 
progression of atherosclerosis rather than in the initiation of the disease. 
 
III.3. Humoral B cell responses 
Initially, the role of B cells was confined to humoral immunity and most of the studies in the 
field of atherosclerosis focused on the characterization of anti-oxLDL antibodies and 
elucidation of their functions. Immunization strategies have been developed by several groups 
to investigate the role of the anti-oxLDL antibodies, in the hope to develop new therapeutic 
strategies to combat atherosclerosis. 
 
IgM antibodies 
B-1 cells secrete natural antibodies that are predominantly IgM and IgA. Both are present 
during the first stage of life despite no contact with foreign antigens, like in the case of 
gnotobiotic mice bred in a completely sterile environment 172. Naive B-1 cells produce most of 
the plasma IgM antibodies and after contact with antigens proliferate and secrete more IgM 
molecules. Direct experimental evidence supporting an atheroprotective role for natural 
antibodies first came from studies showing that Ldlr-/- mice deficient in soluble IgM, that express 
but cannot secrete IgM, developed larger atherosclerotic lesions compared to wild type Ldlr-/- 
mice 173. In humans, levels of plasma IgM against oxLDL are inversely related to atherosclerotic 
plaque size 174 and to ischemic cardiovascular events 175. 30% of all plasma IgM in human and 
mouse bind to oxidation specific epitopes (OSE) 4. The prototype of such IgM is the EO6 IgM 
that was identified from a panel of Apoe-/- mice hybridoma, and was characterized by its ability 
to bind to phosphorylcholine (PC) 176 present on oxLDL, apoptotic cells, as well as on certain 
microbial antigens (reviewed in 2). EO6 had 100% homology with the germ-line encoded T15 
antibody that covalently binds to PC present on the capsule of pathogens 177. These EO6/T15 
antibodies may contribute to the elimination of oxLDL and apoptotic cells, as well as to the 
defense against Streptococcus pneumoniae. Interestingly, splenectomized patients have 
increased susceptibility not only to pneumococcal infections but also to CAD 178. 
Immunization protocols in animal models were subsequently used to investigate the role of 
natural antibodies in atherosclerosis. Immunization of high-fat diet-fed Ldlr-/- mice with heat-
inactivated PC-rich pneumococci 179 induced high titers of plasma anti-oxLDL IgM 
(predominantly EO6) and significantly reduced atherosclerosis. Immunization with oxLDL in 
both atherosclerotic rabbits 180-182 and mice 75, 183, 184 also generated high titers of antibodies 
and reduced atherosclerosis development. Interestingly, immunization with malondialdehyde 
(MDA)-LDL that does not contain PC-exposing oxidized phospholipids induced T15/EO6 
antibodies to levels higher than those found in non-immunized mice fed a high-fat diet 75. 
CIRCRES/2013/302761/R2	
	
	
14
Immunological analysis revealed that MDA-LDL immunization induced a Th2 polarization with 
a production of IL-5 that promoted B1 antibody production. Convincing experiments showed 
that T15/EO6 circulating antibodies were not detectable in IL-5-/- mice and did not increase 
after MDA-LDL immunization. Moreover, IL-5 deficiency in Ldlr-/- mice exacerbated 
atherosclerosis 179. Intriguingly, immunization with native LDL elicited the same level of 
protection as oxLDL immunization 185. Yet, only MDA-LDL immunization yielded high titers of 
antibodies against OSE, suggesting that the antiatherogenic effect of immunization does not 
primarily depend on the production of IgM antibodies against OSE, but more likely results from 
the activation of cellular immune responses. 
In vivo experiments demonstrated the atheroprotective activity of T15/EO6 natural antibodies, 
but the underlying mechanisms remained unknown. In vitro, EO6/T15 bound to the oxidized 
epitopes (lipid and ApoB) of LDL and inhibited their uptake by macrophage scavenger 
receptors 186, specifically CD36 and scavenger receptor class B type I (SR-BI) 187, 188. IgM 
antibodies have been detected in atherosclerotic lesions, colocalizing with macrophage-rich 
area 173. T15/EO6 IgM also bind to oxidized phospholipid-rich apoptotic cells and block their 
pro-inflammatory properties, including endothelial cell activation 189. Moreover, T15/EO6 may 
promote the clearance of apoptotic cells that accumulate within advanced atherosclerotic 
lesions and participate to the growth of the necrotic core 190. Finally, a hypothesis based on the 
binding of IgM with minimally oxLDL that prevent LDL entering into vulnerable sites was 
proposed but not confirmed in experiments that measured the clearance rates of infused 
oxLDL in mice. No difference in the rate of clearance of oxLDL from the plasma was observed 
between immunocompetent Apoe-/- mice and Rag-/-Apoe-/- mice that lack antibodies 191. 
 
IgG antibodies 
IgG is a family of molecules comprised of four members in mice (IgG1, IgG2a, IgG2b, and 
IgG2c/IgG3) and humans (IgG1, IgG2, IgG3, and IgG4). IgG antibodies are produced by B-2 
cells in a Th cell-dependent manner. Th1 and Th2 cells specifically activate mature B cells to 
produce IgG2a and IgG1 subclasses, respectively 192. IFN- is required for IgG2a and IgG3 
production 193, and IL-4 for IgG1. Numerous studies have reported that B-2 cells respond to 
atherosclerosis-associated antigens and produce IgG antibodies. Yet, the distinction between 
antibody-mediated and cellular-mediated effects of B-2 cells on atherosclerosis is difficult to 
define in a precise manner. IgG antibodies reacting against OSE have been detected in the 
plasma and vascular lesions of both patients with CAD and animal models of atherosclerosis 
4, 194. In Ldlr-/- mice, a correlation has been reported between titers of IgG against oxLDL and 
lesion progression 195. In humans, results about the relation between anti-oxLDL IgG molecules 
and CAD are conflicting. In some studies a positive correlation was reported 196-198 whereas a 
negative relationship was found in some others 199. In animal models, immunization protocols 
using MDA-modified LDL led to increased titers of IgG against OSE and a reduction of 
atherosclerotic lesions 180. The inhibition of T-B cell interactions using an anti-OX40L blocking 
antibody resulted in reduced levels of anti-oxLDL IgG1 antibodies, increased levels of IgM and 
reduced atherosclerosis in Ldlr-/- mice 200. 
While accumulating evidence has indicated that IgM antibodies against oxLDL are anti-
atherogenic, the role of anti-oxLDL IgG antibodies has not yet been fully elucidated 2. The 
difference in effect between these isotypes of oxLDL auto-antibodies on atherosclerosis could 
be partially accounted for by the different functions of the specific receptors to which the Fc 
fragment binds. Stimulation of type I Fc gamma receptors (FcγRI), which have high affinity for 
Th1-associated IgG2a 201, on macrophages has been shown to induce inflammatory responses 
202, whereas engagement of FcγRIIb, with low affinity for Th2-associated IgG1 201, elicited 
atheroprotection 203. Interestingly, FcγR γ-chain deficiency in Apoe-/- mice protected against 
atherosclerosis due to the loss of FcγRI and FcγRIIIA, but not FcγRIIb 204. 
 
III.4. Cellular B cell responses 
B cells have classically been thought to contribute to the immune response through 
differentiation into antibody-producing plasma cells. However, human and experimental 
studies have demonstrated that genetic or pharmacologic B-cell depletion can modulate T-
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cell-mediated auto-immune diseases independently of B-cell antibody production, including 
type 1 diabetes and rheumatoid arthritis, which suggests that the cellular functions of B cells 
are important in the regulation of the adaptive immune response 205. B cells, in addition to 
producing antibodies, also secrete cytokines 206. For example, B cell-derived lymphotoxin  
(LT) and TNF- control the development of follicular DCs and the formation of B cell follicles 
in the spleen. Also, in the context of myocardial infarction, B cells can release CCL7/MCP-3 
that stimulates the mobization of monocytes from the bone marrow into the circulation 207. 
In an attempt to explore the role of B cells in atherosclerosis, splenectomy was performed in 
Apoe-/- mice 208. This led to a reduction of T- and B-cell pools, associated with accelerated 
atherosclerosis. In addition, transfer of splenic B cells from Apoe-/- mice reversed the vascular 
phenotype, suggesting a protective role of mature B cells. This finding was supported by data 
showing that bone marrow transplantation from μMT mice, deficient in B cells, into Ldlr-/- mice 
increased atherosclerosis 209. Intriguingly, a reduction of T cell activation was also observed in 
this study. Even though these studies document an atheroprotective role of B cells, it was not 
clear whether this was mediated through cellular or humoral responses. 
Recent studies allowed us to better understand the role of humoral and cellular functions of B 
cells in atherosclerosis. Experimental protocols based on anti-CD20 depleting antibody 
administration induced a marked and prolonged depletion in mature B cells (more than 95% in 
the spleen, the blood and the lymph nodes) with little effect on B-1 cells in the peritoneal cavity 
of atherosclerosis-prone mice 210. The depletion of B cells led to decreased atherosclerotic 
lesions in Apoe-/- and Ldlr-/- mice fed a chow or high fat diet 210, 211. Plasma levels of natural IgM 
were unchanged following B-cell depletion, likely due to minimal depletion of peritoneal B-1a 
cells, but the titers of IgG antibodies against oxLDL were markedly reduced. Moreover, B-cell 
depletion also reduced activation and proliferation of DCs and CD4+ T cells, which was 
associated with decreased IFN- but increased IL-17 production 210. Transfer of purified B-2 
cells increased titers of IgG antibodies and atherosclerotic lesions, whereas B-1a transfer 
restored natural IgM antibody pool and reduced atherosclerosis 210, 211. The transfer of B-1a 
cells from sIgM-/- mice did not protect against atherosclerosis, confirming that the protective 
effect of B-1a cells was mediated by IgM. Of note, transfer of B-1a cells also diminished the 
accumulation of apoptotic cells within atherosclerotic plaques, in agreement with the role of 
natural IgM antibodies in the clearance of dead cells 212. B cell-activating factor (BAFF)/BAFF 
receptor (BAFFr) interactions are important for B cell survival and maturation. BAFF receptor 
deletion selectively depletes B-2 cells, with no effect on B-1 cells, and reduces T cell activation. 
The transfer of bone marrow from BAFFr deficient mice into Ldlr-/- mice reduced 
atherosclerosis, which confirms the proatherogenic activity of mature B-2 cells 213. More 
recently, a proatherogenic role has been attributed to the newly identified IRA B cells by 
promoting the expansion of classical DCs and Th1 polarization 164.  
Recent important advances have extended our knowledge of the role of B cells in 
atherosclerosis, underscoring the protective function of B-1a cells through IgM secretion and 
the pathogenic effect of B-2 and IRA B cells that amplify the immune-inflammatory response 
through T cell activation and Th1 polarization (Figure 3). New therapeutic strategies based on 
B-1a cell expansion or B-2 depletion could be designed in the future to combat atherosclerosis. 
 
 
IV. Role of Dendritic cells in atherosclerosis 
DCs are the most important APCs that drive the maturation and polarization of naive T cells 
recognizing specific MHC-presented antigenic peptides, with the nature of the T cell response 
dependent on DC status determined by signals received by pattern recognition receptors, 
membrane-bound costimulation and cytokines 214. Immature DCs, phenotypically 
characterized by the expression of few costimulatory molecules induce T cell death, anergy, 
or skewed differentiation toward a regulatory phenotype 215, thus can also be thought of as 
“tolerogenic”. In addition to immature DCs, mature or activated DCs receiving strong anti-
inflammatory signals such as TGF- or IL-10 are also tolerogenic, thus the T cell stimulatory 
capacity of DCs is not as simple as an immature/mature dichotomy. DCs are also instrumental 
in defining the type of effector T cell formed. For example, IL-12 produced by DCs is central in 
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Th1 differentiation whereas IL-6 promotes a Th-17 response 216. The activation of both effector 
and memory T cells is not restricted to DCs, however, and involves other APCs such as B cells 
and macrophages 217.  
 
IV.1. DC ontogeny and subsets in atherosclerosis 
DCs originate from CD34+ bone marrow precursors of the myeloid lineage (common myeloid 
precursors (CMPs)) 218, 219. Immature DCs circulate via the bloodstream and populate tissues, 
mainly close to epithelial and body cavity surfaces, where they serve as sentinels of infection 
or injury 220. In general terms, the different sublineages of DCs found in mice and humans are 
now well characterized 221, 222, although debate and blurring of phenotypes remains between 
monocyte-derived “macrophages” and “DCs” in inflammatory tissue such as atherosclerotic 
plaque. DCs, defined by their primary function of presenting antigen to T cells, have 3 major 
precursors in the blood (Figure 4): Fms-like tyrosine kinase 3 (Flt3)+ pre-classical DCs (cDCs), 
colony-stimulating factor 1 receptor (CSF1R)+ monocytes and Flt3+ plasmacytoid DCs (pDCs), 
with both Flt3+ populations originating from a common dendritic precursor (CDP) that arises 
from CMPs 223, 224. Transcription factors influencing these lineages include Zbtb46 and BATF3 
for pre-cDCs 221 and Tcf4 for pDCs 225, 226. Pre-cDCs directly entering lymphoid tissue become 
specialized lymphoid resident DCs. Pre-cDCs entering peripheral tissues are classed as 
migratory DCs that are the classic sentinels that sample antigen and once activated by innate 
signals, such as TLR ligands, migrate to draining lymph nodes enabling interactions with 
multiple T cells. In both cases, pre-cDCs differentiate into CD103+ (CD8+ in lymphoid tissue) 
and CD11b+ (or CD4+) cDC subsets. Monocytes, in addition to becoming macrophages of 
various mature phenotypes, can form CD11b+ DCs that express DC associated antigens such 
as DC-SIGN and possess high T cell stimulatory but low phagocytic capacity 227. Defining 
monocyte-derived cells as macrophages or DCs and functional subsets thereof is a subject of 
much debate. 
In the context of understanding links with adaptive immunity, myeloid cells of several 
phenotypes express significant levels of MHCII 227, 228	 and thus likely contribute to T cell 
activation within atherosclerotic plaques. Although CD11c is expressed by nearly all plaque 
monocyte-derived cells, the presence of CD11c+ cells negative for expression of macrophage 
markers such as CD68 and F4/80 suggests the presence of distinct myeloid DCs 227, 228. Zbtb46 
is a transcription factor expressed by monocyte-derived DCs and cDCs, but not macrophages 
or pDCs 221 and represents an important novel marker to aid in understanding plaque myeloid 
subsets. Recently, a subset of CCL17+ DCs that express high levels of co-stimulatory 
molecules (CD40, CD80, CD86) has been described within the atherosclerotic plaque but its 
specific origin remains unclear 127. Transcription factor E2-2 effectively differentiates pDCs 
from other DC subsets, as does the surface marker Siglec-H 225. The most well characterized 
function of pDCs is to rapidly produce large amounts of type-I IFN in response to viral infection. 
However they can also take on mature cDC-like phenotypes and regulate T cell responses via 
antigen presentation 229 and promote Treg function through indoleamine 2,3-dioxygenase 
(IDO) 230. A growing literature has identified significant contributions of pDCs to autoimmune 
diseases in addition to viral infections. 
In normal arteries, DCs were identified 231 along the subendothelial intima layer and also in the 
adventitia, close to the vasa vasorum 232. In atherosclerosis-prone regions, such as the lesser 
curvature of the aortic arch, DCs are present in higher numbers 227, 233-235 including 
CD11c+CD11b−CD103+ DCs derived from pre-cDC and CD11c+CD11b+CD103−DCs derived 
from monocytes 227. This last subset accounts for the majority of CD11c+ cells in more 
advanced plaques and likely originates from circulating monocyte precursors 227. Mature DC 
accumulate in mouse and human atherosclerotic lesions with a marked increase in advanced 
stages and in complicated plaques 236. DCs also accumulate in adventitial TLOs 171. pDCs are 
present in human and mouse atherosclerotic plaque in small numbers 230, 237, 238. It is also 
possible that since in some activation contexts pDCs become cDC-like in phenotype, further 
pDC-derived cells exist in plaques. Indeed in general, all DC subsets converge in terms of 
transcriptional profile in response to multiple activation signals 239. Thus, DCs with various 
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ontogeny and surface phenotype are present throughout the natural history of plaque 
development. 
 
IV.2. Functional roles for DCs in atherosclerosis 
An unexpected finding resulting from studies manipulating DC numbers has been the effects 
on cholesterol homeostasis, precluding unequivocal conclusions on the influences of their 
immune functions in atherosclerosis. Depleting CD11c+ cells in CD11c-DTR mice led to 
enhanced cholesterol levels and no change in atherosclerosis, an interpretation of which is 
that higher cholesterol but lower DC-driven T cell immunity cancel each other out 240. Enhanced 
macrophage apoptosis had a similar effect 241. Another study with the same mice reported that 
these mice also develop a progressive myeloproliferative state, suggesting indirect effects on 
the hematopoietic system with prolonged depletion of peripheral cDCs 242. Conversely, 
prolonging CD11c+ cell survival by Bcl2 overexpression had the opposite effects on cholesterol 
and also did not change atherosclerosis 240. Intimal DCs were shown to form foam cells in the 
aortic intima 243 and using CD11c-DTR mice in very short term high fat diet experiments, the 
lack of these intimal DCs dramatically reduced the lipid area, suggesting that DCs may be 
instrumental in the first stages of atherosclerosis. Overall, these studies failed to demonstrate 
DC antigen presentation function as pro-atherogenic, as has long been hypothesized, whereas 
Koltsova et al demonstrated that, ex vivo, aorta resident APCs can promote TNF- and IFN- 
production by T cells from Apoe-/- but not WT mice 228. Alternative approaches will be necessary 
to target this aspect more specifically. In contrast, a number of studies now highlight an 
important role for cDCs in maintaining anti-atherosclerotic regulatory T cells. (Figure 4). 
Regulatory T cell survival and hometostatic proliferation critically depend on continued 
interactions with APCs, presumably presenting the relevant autoantigen in a tolerogenic 
context. For example, blocking DC maturation through CD11c-specific knockdown of MyD88 
altered the Treg cell pool and accelerated atherosclerosis 244. This is further supported by 
experiments showing that lack of ICOS or PD-1, inhibitory pathways of the TNF superfamily, 
reduce Treg cell capacity and lead to increased atherosclerosis, as does treatment with 
CTLA4-Ig (Abatacept) 245, 246, which disrupts CD28-CD80/86 interactions. In terms of defining 
which subsets of cDCs are involved, Choi et al demonstrate that the majority of Flt3+ pre-cDC 
derived cells in normal and atherosclerotic plaques are CD103+ DCs and that Flt3 deficiency 
increases atheorsclerosis 227, whereas CCL17+ DCs prevent the differentiation of naïve T cells 
into Treg cells through CCR4 and thus promote atherosclerosis 127. Combining these studies 
leads to the conclusion that CD103+ cDC MyD88 signaling is vital for maintaining regulatory T 
cells and that this is antagonized in atherosclerosis by the induction of CCL17+ CD11b+ cDCs. 
The signals that lead to DC maturation in atherosclerotic lesions remain unknown, but 
numerous candidates include inflammatory cytokines, TLR ligands, nuclear fragments derived 
from necrotic cells and (oxidized) lipids. The multiple roles of TLRs and their ligands in 
atherosclerosis are reviewed in detail elsewhere 247, 248. In vitro, oxLDL strongly modifies 
human DC phenotype with an up-regulation of surface T cell-stimulatory molecules (CD40, 
CD86 and HLA-DR), scavenger receptor expression (CD36) and increased cytokine 
production 249, 250. Systemically, though, T cell responses to exogenous immunization were not 
changed in hypercholesterolemic conditions 251. DC and MHCII co-localization 252 and frequent 
contacts between DCs and T cells observed within the atherosclerotic plaques suggest local 
interactions and specific T cell stimulation 236 (Figure 4). Indeed, CD11c+ cells present in aortic 
explants interact in an antigen-specific manner with exogenously added T cells 253. Data from 
animal models show that genetic deletion of important co-stimulatory molecules (CD80/CD86) 
in mice reduces T cell activation/infiltration and reduces atherosclerosis 254. The inability of 
CD11c+ cells to respond to anti-inflammatory TGF- signaling due to conditional deficiency in 
TGF-BRII leads to enhanced TNF and IL-12 production by DCs and increased atherosclerosis 
255. pDCs are a major source of pro-atherogenic type I IFN, but their role in atherosclerosis is 
still under debate as the depletion using an antibody against bone marrow stromal cell antigen-
2 (BST-2/PDCA1) had opposite effects on Ldlr-/- and Apoe-/- mouse models of atherosclerosis 
230, 237, 238, and this antigen is not entirely pDC-specific. Nevertheless, a potentially important 
role is indicated and deserves further attention, especially since alternative genetic approaches 
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are now available, including pDC specific DTR transgenic mice 256 and pDC deficient mice 225. 
The latter mice, which lack the E2-2 transcription factor critical for pDC differentiation only in 
DCs, interestingly highlight the ability of pDCs to become cDC-like cells, which has been 
reported to also occur in a number of infection and autoimmune contexts. Given that the 
existing studies on pDC roles in atherosclerosis each highlighted distinct molecular 
mechanisms, it will be important to further explore pDC functions beyond type I IFN production, 
such as antigen presentation 238 or Treg stimulation via IDO 230. 
The central role of DCs in the modulation of the adaptive immune response has been illustrated 
by DC-based vaccination strategies against atherosclerosis, showing that intravenous injection 
of oxLDL-loaded DCs in mice induced an attenuation of flow-induced atherosclerosis and a 
stabilization of plaque phenotype in carotid arteries 257. Also, transfer of DCs loaded with ApoB-
100-derived peptides and incubated with IL-10, known to induce a tolerogenic phenotype led 
reduced atherosclerosis as well as the systemic and local inflammatory responses in human 
ApoB-100-transgenic Ldlr-/- mice 258. These pre-clinical studies suggest that DC-based 
vaccination could represent a new approach to treat atherosclerosis. 
 
 
V.  Unresolved questions  
In atherosclerosis, the precise site of DC-mediated antigen presentation to T cells remains 
unknown. The identification of oligoclonal T cell infiltration in human atherosclerotic plaques 40 
and the frequent contacts between T and DCs within the lesions 236 raised the hypothesis of 
direct antigen presentation in the vascular wall. Using a model of live-cell imaging on explanted 
aorta from mice, these DC-T cell interactions were visualized in the adventitia 253. Interestingly, 
T cells isolated from hypercholesterolemic animals interacted in vitro with adventitial APCs to 
a much greater extent than T cells from naive BL6 mice, providing evidence for atherosclerosis 
antigen-specific T cells and the possibility of local presentation of those antigens by vascular 
wall APCs. However, there is still no information whether this happens in vivo and where naive 
T cells are sensitized. What this observation suggests is that DCs might interact with effector 
or memory T cells in the vascular wall, but not with naive T cells. Yet, the site of initial antigen 
encounter is still unknown for both DCs and T cells, with several viable possibilities. DCs might 
take up antigen(s) in lesions and migrate to lymph nodes, or they might ingest circulating 
antigens (i.e., in spleen) for effective antigen presentation. Morever, it is unclear whether T 
cells are primed in lymph nodes or spleen, or in TLOs. Indeed, despite abundant levels found 
in plaques, both oxLDL and Hsp65 can be found in the blood and are also likely to be present 
at high concentrations in lymph leaving plaque and entering the draining adventitial lymphatics 
259. Although many myeloid cells may not ever leave plaques at advanced stages 260, some DC 
departure dependent on Ccl21-Ccr7 chemotaxis is possible 261, 262. DCs in the adventitia could 
also act as migratory DCs, or could conceivably present antigen in situ. Whether naïve T cells 
can exit capillaries and interact with DCs in the adventitia is unknown. However, since the 
adventitia is a site of future tertiary lymphoid tissue, this is an intriguing possibility. Circulating 
antigen could alternatively be taken up by resident lymphoid DCs, particularly, for example, if 
complexed with low affinity antibodies produced by innate B cells. 
DC trafficking is another topic of controversy. Experiments using aortic transplantation in mice 
identified CCR7 and its ligands CCL-19/CCL-20 as an important regulator of DC emigration 
from the atherosclerotic lesion 261. However, in a model of atherosclerosis regression, the 
emigration of myeloid cells was not affected by CCR7 deficiency 260. 
Specific antigen-driven T cell immunity in atherosclerosis 
Adaptive immunity is an intelligent response against selective (auto)antigens, and the 
oligoclonal TCR repertoire of T cells that infiltrate human atherosclerotic plaque argues for the 
selectivity of the adaptive immune response in atherosclerosis. However, definitive 
identification of these antigens remains unsolved. Two serious candidates have been 
proposed based on human and experimental studies, Hsp60 and LDL-associated peptides. 
Hsp are cytosolic, highly conserved molecular chaperones involved in several auto-immune 
diseases such as multiple sclerosis or rheumatoid arthritis 263, although they are also found 
extracellularly in chronic inflammatory tissues. Hsp60 has been detected by 
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immunohistochemical staining in human atherosclerotic samples 264. Immunization against 
Hsp65 in hypercholesterolemic rabbits induced Hsp-65-reactive T cells and accelerated 
atherosclerosis 265. In Ldlr-/- mice, Hsp65 immunization also increased lesion size in the aortic 
sinus and T cell infiltration within the vascular wall 266. Moreover, the transfer of T cell isolated 
from Hsp65-immunized mice accelerated atherosclerosis in Ldlr-/- animals 267. In contrast, 
induction of tolerance by nasal administration of Hsp65 reduced atherosclerotic lesion size and 
T cell infiltration. This protocol strongly modulated CD4+ T cells in draining lymph nodes with a 
reduction of IFN- and increased IL-10, suggesting an expansion of Tr1-like Treg cells 133. 
LDL-associated peptides represent another major source of putative autoantigens whose role 
has been highlighted by studies that explored the natural antibody response to oxLDL 
(reviewed in 2, 4). T cells isolated from human plaques can proliferate in a MHCII-dependent 
manner in the presence of oxLDL 29. More recently, T cell clones that recognize native 
oligopeptides of ApoB-100 protein were also reported 136. Adoptive transfer of oxLDL-reactive 
T cells in Apoe-/- boosted Th1 immunity and accelerated atherosclerosis 268. In contrast, other 
strategies focused on antigen-specific Treg cell expansion, including subcutaneous 
administration of low doses of ApoB-100 derived-peptides 138 or injection of ApoB-100-loaded 
DCs 136, have been shown to reduce the disease in Apoe-/- mice. Recently, ApoB-100 peptides 
characterized as having high affinity for MHCII were also effective in reducing atherosclerosis 
269. 
Mechanisms of self-tolerance normally inhibit the maturation and/or activation of T cells 
specific for LDL-associated peptides and Hsp60. There are several explanations why T-cell 
responses against normally tolerated self-proteins may occur. First, self-proteins modified in 
vivo by oxidation are recognized as non-self molecules 270. Moreover, molecular mimicry 
between self-proteins and microbial particles could affect the discriminative functions of the 
immune system with bacteria-reactive T cells that target “by mistake” homologous self-proteins 
271. Finally, the environment surrounding antigen presentation could affect T-DC interactions. 
In the context of atherosclerosis, the accumulation of apoptotic cells generates membrane 
derived oxidized phospholipids or DNA fragments, which can be recognized by the innate 
immune system as DAMPs 272, leading to DC activation through pattern recognition receptors 
(TLRs or NODs) and resulting in break of tolerance to self antigens. As an example, the genetic 
invalidation of Mfge-8 or MertK, both proteins implicated in apoptotic cell clearance induced an 
accumulation of cell debris, activation of DCs and deviation of T cell responses toward a pro-
atherogenic Th1 profile 190, 273, 274. 
 
 
VI. Conclusion 
Recent investigations of the immune responses in atherosclerosis have revealed a previously 
unappreciated complexity. Studies of immune-deficient mice on an atherosclerosis prone 
background have uncovered dual roles for the immune system in suppressing and promoting 
atherosclerosis. In these systems, the interplay of innate immunity, adaptive immunity and 
inflammation helps determine the outcome of the atherosclerotic process. Future work should 
aim at characterizing the immune pathways in patients with CAD to establish whether 
comparable alterations of immune functions contribute to atherosclerosis in humans. 
Immunological biomarkers that reflect T/B cell activation or Th cell polarization (Th1, Th2, 
Th17, Treg), predictive for the specific type of immune response should allow us to better 
define the immune phenotype of patients with CAD, and eventually improve stratification of 
patients with high cardiovascular risk. For instance, single nucleotide polymorphisms (SNPs) 
in several cytokine or immune-cell activation/signaling pathway genes have been reported. 
These SNPs might result in imbalance in Th cell polarization and contribute to clinical 
outcomes 275. 
Therapeutic manipulations that are aimed at restoring defective immune functions, such as 
Treg or B-1 cell activity, or attenuating proatherogenic immune action, such as Th1, B-2 or IRA 
B cell activity, might reduce atherosclerosis development and progression. Taking into account 
the inter-individual diversity in the adaptive immune response would add to the benefit of 
current treatments of cardiovascular risk factors. Strategies for vaccination or tolerance 
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induction have already proven beneficial in animal models by stimulating B-1 activity and 
restoring Treg function, respectively. Molecules used in the treatment of autoimmune diseases 
such as anti-CD20 antibodies to deplete conventional B-2 cells, which protect against 
atherosclerosis in mice, may also benefit patients with CAD. The dual role of adaptive immunity 
in atherosclerosis further implies that immunotherapies should target several pathways. 
Combined approaches to both stimulate protective immune responses and inhibit pathogenic 
immune reactions are likely to prove most efficient.  
Finally, a recent report showing that bacterial metabolites from commensal microorganisms 
regulate the immune system by promoting peripheral Treg cell expansion 276 open new 
avenues for studying the communication between microbiota, adaptive immunity and 
atherosclerosis. 
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Figure 1. Innate and adaptive cellular response. 
Innate immune cells are characterized by a rapid but poorly specific responses whereas  
daptive responses are more delayed but specifically recognize epitopes. Strong interactions 
between innate and adaptive systems have been highlighted during the last decade with 
several cell subsets positioned at the interface between both systems. 
NK, Natural Killer; Treg, regulatory T cells; ILC2, Type 2 Innate Lymphoid Cells.; IRA B cell: 
innate response activator B cell 
 
 
Figure 2. Differentiation, activation, and interactions between CD4+ T cell subsets. 
Mature dendritic cells polarize naive Th0 cells into different effector T cells through antigen 
presentation to the TCR, secretion of cytokines and costimulation. Th1, Th2 or Th17 cells are 
categorized by the transcription factors they express and the cytokines they release. The 
archetypical cytokine of each subset is marked in bold. Tolerogenic dendritic cells prime Th0 
cells toward a Treg phenotype. The complex interactions between the various CD4+T cell 
subsets involved in atherosclerosis are represented schematically. 
DAMPs, Danger-associated molecular patterns; CTLA‑4, cytotoxic T‑lymphocyte antigen 4; 
Foxp3, forkhead box protein P3; IL, interleukin; ROR, RAR-related orphan receptor; STAT, 
signal transducer and activator of transcription; TBX21, T‑box transcription factor TBX21 
(also known as T‑bet); TCR, T‑cell receptor; MHC, Major histocompatibility complex; TGF‑β 
1, transforming growth factor β 1; Th , T‑helper cell; TNF, tumor necrosis factor; IFN, 
Interferon; Treg, T‑regulatory; Hsp, heat shock protein, oxLDL, oxidized low density 
lipoprotein. 
 
Figure 3. B cell responses in atherosclerosis. 
B-1a cells have been shown to be atheroprotective mainly through the release of anti-oxLDL 
antibodies. B-2 cells promote atherosclerosis, stimulate T/DC activation and Th1 polarization. 
IRA B cells secrete GM-CSF, promote DC expansion and Th1 polarization. Therapeutic 
strategies based on B-1a expansion (immunization protocol) or B-2 depletion (anti-CD20 
antibody, Baff-R invalidation) have been shown to reduce atherosclerosis in experimental 
models. 
BAFF, B-cell activating factor 
 
Figure 4. Dendritic cell subsets in atherosclerosis. Dendritic cells in lymphoid organs and 
potentially vascular adventita derive from Flt3+ pre-cDCs directly from blood or migrating from 
peripheral tissues and form CD103+ or CD11b+ subsets. CD11b+ DCs also derive from 
monocytes and possibly pDCs. Flt3+ precursor derived CD103+ DCs maintain Tregs through 
multiple pathways including MyD88 dependent signaling and co-inhibitory interactions such 
as ICOS or PD-L1, whereas CCl17+ CD11b+ DCs suppress Tregs. CD80/86 and CD40 
signaling as well as IL-12 production from mature DCs promotes naive T cell differentiation 
into pro-atherogenic Th1 cells. Within plaques, pre-cDC derived DCs are prominent foam 
cell-forming cells in very early lesions, whereas at later stagesmonocyte-derived DCs (and 
macrophages) recruit and activate proatherogenic Th1 cells through CCL17 production, 
antigen presentation and costimulatory signals. 
cDC, conventional Dendritic Cell; pDC, plasmacytoid Dendritic Cell; ICOS, Inducible 
Costimulator; PD-L1, Programmed cell death ligand 1 
 




